Joshua Meeks, MD
Urology · Chicago, ILNPI 1821248014
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $180,668 of the $248,144 with a category attached, or 72.8%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.9%. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $1008.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$54K
- Janssen Research & Development, LLC$53K
- Ferring Pharmaceuticals Inc.$25K
- Astrazeneca UK Limited$22K
- Urogen Pharma, Inc.$21K
- Janssen Global Services, LLC$16K
- plus $57K from 19 others
Across 166 payments — averaging $10,478 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$976K
- Janssen Research & Development, LLC$592K
- Pfizer$67K
- Photocure Inc$40K
- Incyte Corporation$25K
- Seagen Inc.$21K
- plus $18K from 2 others
What the payments were for
- Consulting fees$180,66873%
- Speaking & faculty fees$8,6253%
- Travel & lodging$4,6012%
- Food & beverage$3,5941%
- Education$50,65720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 103 | $54,245 |
| Janssen Research & Development, LLC | 25 | $53,261 |
| Ferring Pharmaceuticals Inc. | 15 | $24,895 |
| Astrazeneca UK Limited | 24 | $22,153 |
| Urogen Pharma, Inc. | 6 | $21,183 |
| Janssen Global Services, LLC | 19 | $15,615 |
| Merck | 10 | $11,673 |
| Ferring Pharmaceuticals AS | 2 | $11,284 |
| Pfizer | 7 | $8,531 |
| AstraZeneca | 8 | $5,742 |
| Foundation Medicine, Inc. | 4 | $4,387 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,814 |
| Astellas Pharma Global Development | 4 | $3,599 |
| Immunitybio, Inc. | 1 | $2,400 |
| Astellas Pharma US Inc | 3 | $2,384 |
| Olympus Corporation | 2 | $900 |
| Janssen Scientific Affairs, LLC | 1 | $758 |
| Gyrus ACMI, Inc. | 1 | $730 |
| Seagen Inc. | 2 | $176 |
| Photocure Inc | 2 | $169 |
| Medical Device Business Services, Inc. | 1 | $108 |
| Genentech, Inc. | 1 | $57 |
| Antares Pharma, Inc. | 1 | $44 |
| Olympus America Inc. | 1 | $23 |
| Hollister Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OES CYSTONEPHROFIBERSCOPE$46,214
- CYSTO-NEPHRO VIDEOSCOPE$46,036
- HD CAMERA HEAD$29,483
- ADSTILADRIN$18,163
- Olympus$15,755
- HD 3CMOS AUTOCLAVABLE CAMERA HEAD$15,755
- IMFINZI$15,039
- Single Use Grasping Forceps FG-253SX$13,820
- JELMYTO$13,600
- PADCEV$11,004
- Olympus Laser Devices$7,881
- Olympus Cystoscopes$7,881
- Olympus Resection Disposables$7,881
- Balversa$4,960
- FOUNDATIONACT$4,387
- FOUNDATIONFOCUS$4,387
- FOUNDATIONONE CDX$4,387
- FOUNDATIONONE HEME$4,387
- FOUNDATIONONE$4,387
- OPDIVO$3,814
How this compares
$248,144 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $4,964 |
| Tamsulosin Hcl | 92 | $2,019 |
| Oxybutynin Chloride ErOxybutynin Chloride | 39 | $716 |
| Finasteride | 26 | $482 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 16 | $332 |
| Ciprofloxacin Hcl | 24 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $2,384 | $4,96411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 urology providers in Illinois.
Other urology in Chicago
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
- Edward SchaefferChicago$209K
- Paul YonoverChicago$179K
- Omer RaheemChicago$148K
- Piyush AgarwalChicago$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.